| For Nut Benefits, More Is Better More research backing up the cholesterol-lowering benefits of eating nuts indicates that for most people, consuming two handfuls of nuts a day appears to work better than one. online.wsj.com |
Celgene: Growth by Acquisition Jason Chew submits: During the last decade, Celgene (CELG) has been one of the best performing stocks. With a market cap in the year 2000 of just $2.4 billion, it has grown to become the third largest biotech company behind Amgen (AMGN) and Gilead (GILD), sporting a $22.9 billion market cap; however, that is down from its recent high of over $30 billion. Its stock has been trending downward since 2008.Its top drug, Revlimid, was initially approved in 2005 for a subset of myelodysplastic syndrome (MDS) patients after a highly successful Phase II trial. It went on to gain approval in multiple myeloma (MM), with sales hitting $1.7 billion in 2009. Complete Story » seekingalpha.com |
Cephalon Q2 2010 Earnings Call Transcript Cephalon (CEPH)Q2 2010 Earnings CallJuly 27, 2010 5:00 pm ETComplete Story » seekingalpha.com |
NuPathe Trades at Discount to IPO Price with Near-Term FDA Filing Mike Havrilla submits:NuPathe (NASDAQ:PATH) completed its initial public offering (IPO) on 8/6/10 at $10 per share for 5 million shares of common stock, raising $43 million in net proceeds. The Company's stock is currently trading at a 20% discount at $8 per share with a market cap of $116 million and expects to submit a New Drug Application (NDA) through the 505(b)(2) pathway, representing a novel formulation of a previously approved drug compound.NuPathe ended 2Q10 with $51.5 million in cash/equivalents, which includes net proceeds received from the IPO in early August. The Company reported a net loss of $5.6 million during 2Q10, including $3.3 million for research & development (R&D).Complete Story » seekingalpha.com |
Keeping Tabs on Joint Replacements A new nationwide registry will collect data on hip and knee replacements in order to uncover implant problems more quickly. online.wsj.com |